Abstract:Background: Many human diseases are associated with dysregulation of HDACs. HDAC6 exhibits deacetylase activity not only to histone protein but also to non-histone proteins such as α- tubulin, HSP90, cortactin, and peroxiredoxin. These unique functions of HDAC6 have gained significant attention in the medicinal chemistry community in recent years. Thus a great deal of effort has devoted to developing selective HDAC6 inhibitors for therapy with the hope to minimize the side effects caused by pan-HDAC inhibition. Objective: The review intends to analyze the structural feature of the scaffolds, to provide useful information for those who are interested in this field, as well as to spark the future design of the new inhibitors. Methods: The primary tool used for patent searching is SciFinder. All patents are retrieved from the following websites: the World Intellectual Property Organization (WIPO®), the United States Patent Trademark Office (USPTO®), Espacenet®, and Google Patents. The years of patents covered in this review are between 2016 and 2019. Results: Thirty-six patents from seventeen companies/academic institutes were classified into three categories based on the structure of ZBG: hydroxamic acid, 1,3,4-oxadiazole, and 1,2,4-oxadiazole. ZBG connects to the cap group through a linker. The cap group can tolerate different functional groups, including amide, urea, sulfonamide, sulfamide, etc. The cap group appears to modulate the selectivity of HDAC6 over other HDAC subtypes. Conclusion: Selectively targeting HDAC6 over other subtypes represents two fold advantages: it maximizes the pharmacological effects and minimizes the side effects seen in pan-HDAC inhibitors. Many small molecule selective HDAC6 inhibitors have advanced to clinical studies in recent years. We anticipate the approval of selective HDAC6 inhibitors as therapeutic agents in the near future.

Recent Development of Novel HDAC6 Isoform-Selective Inhibitors.

[Histone Deacetylase 6: Structure, Functions and Development of Selective Inhibitors].

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Structure, Functions and Selective Inhibitors of HDAC6

Hdac6: Physiological Function And Its Selective Inhibitors For Cancer Treatment

Inhibition of HDAC6 Activity in Kidney Diseases: a New Perspective

Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design

Histone deacetylase 6 in cancer

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives As HDAC6 Isoform-Selective Inhibitors.

Posttranslational Modification and Beyond: Interplay Between Histone Deacetylase 6 and Heat-Shock Protein 90

Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances

Curriculum vitae of HDAC6 in solid tumors

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

New Development of HDAC Inhibitors As Anti-Cancer Agents

The emerging roles of HDACs and their therapeutic implications in cancer

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Biological Function and Small Molecule Inhibitors of Histone Deacetylase 11

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition